Jennison Associates’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-348,817
| Closed | -$30.9M | – | 587 |
|
|
2025
Q1 | $30.9M | Sell |
348,817
-11,391
| -3% | -$1.01M | 0.02% | 270 |
|
|
2024
Q4 | $31.4M | Buy |
+360,208
| New | +$31.4M | 0.02% | 292 |
|
|
2022
Q1 | – | Sell |
-251,237
| Closed | -$26.9M | – | 638 |
|
|
2021
Q4 | $26.9M | Sell |
251,237
-144,893
| -37% | -$15.5M | 0.02% | 315 |
|
|
2021
Q3 | $40.7M | Sell |
396,130
-8,371
| -2% | -$861K | 0.03% | 247 |
|
|
2021
Q2 | $35.6M | Sell |
404,501
-8,412
| -2% | -$740K | 0.02% | 277 |
|
|
2021
Q1 | $40.1M | Buy |
412,913
+391,572
| +1,835% | +$38.1M | 0.03% | 247 |
|
|
2020
Q4 | $2.39M | Buy |
+21,341
| New | +$2.39M | ﹤0.01% | 489 |
|
|
2020
Q2 | – | Sell |
-61,058
| Closed | -$3.57M | – | 633 |
|
|
2020
Q1 | $3.57M | Buy |
61,058
+416
| +0.7% | +$24.3K | ﹤0.01% | 420 |
|
|
2019
Q4 | $4.86M | Sell |
60,642
-47,408
| -44% | -$3.8M | ﹤0.01% | 431 |
|
|
2019
Q3 | $7.94M | Sell |
108,050
-79,635
| -42% | -$5.85M | 0.01% | 427 |
|
|
2019
Q2 | $17.7M | Sell |
187,685
-373
| -0.2% | -$35.2K | 0.02% | 369 |
|
|
2019
Q1 | $15.1M | Buy |
188,058
+209
| +0.1% | +$16.7K | 0.01% | 396 |
|
|
2018
Q4 | $10.1M | Sell |
187,849
-34,691
| -16% | -$1.87M | 0.01% | 432 |
|
|
2018
Q3 | $17.4M | Buy |
222,540
+1,658
| +0.8% | +$129K | 0.02% | 414 |
|
|
2018
Q2 | $14M | Buy |
220,882
+12,408
| +6% | +$788K | 0.01% | 440 |
|
|
2018
Q1 | $19.1M | Buy |
208,474
+28,389
| +16% | +$2.6M | 0.02% | 396 |
|
|
2017
Q4 | $13.6M | Sell |
180,085
-48,532
| -21% | -$3.66M | 0.01% | 443 |
|
|
2017
Q3 | $15.9M | Sell |
228,617
-525
| -0.2% | -$36.6K | 0.02% | 433 |
|
|
2017
Q2 | $11.6M | Buy |
229,142
+79,142
| +53% | +$4.01M | 0.01% | 460 |
|
|
2017
Q1 | $6M | Buy |
+150,000
| New | +$6M | 0.01% | 498 |
|